-
AJH: Sutizumab can effectively prevent the exacerbation of hemolytic anemia in patients with cold agglutinin disease undergoing major surgery
Time of Update: 2021-12-01
A foreign research team described a white male who had a 10-year history of coronary heart disease (CHD), with three right coronary artery (RCA) stents for myocardial infarction as a manifestationSutizumab is a complement c1 inhibitor that can selectively block classic complement activation, but retains the alternative and lectin pathways .
-
NEJM: AAV gene therapy for hemophilia, with significant effect and good safety
Time of Update: 2021-12-01
It is the ultimate goal of researchers to safely deliver coagulation factor VIII to patient cells through gene therapy, allow it to be stably expressed for a long time, and use a very low vector dose to improve the patient's bleeding and coagulation function .
-
Clin Cancer Res: Long-term prognosis of Tislelizumab in the treatment of relapsed/refractory classic Hodgkin's lymphoma
Time of Update: 2021-12-01
This article reports the results of a phase II clinical trial of Tislelizumab for the treatment of 70 patients with relapsed/refractory classic Hodgkin’s lymphoma and extended follow-up for 3 years .
Tislelizumab for relapsed/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis .
-
NEJM: The effect of Daprodustat in the treatment of anemia in non-dialysis patients with chronic kidney disease
Time of Update: 2021-12-01
In short, in patients with chronic kidney disease with anemia who have not undergone dialysis treatment, the effect of daprestat is not inferior to that of afadabepo in terms of changes in hemoglobin levels and cardiovascular outcomes .
-
Boshengji Pharmaceutical's CD7-targeted CAR-T cell injection obtained the U.S. FDA orphan drug designation
Time of Update: 2021-12-01
(hereinafter referred to as "Boshengji") announced its development of CD7-targeted chimeric antigen receptor (CAR)-T cell injection (PA3-17 injection) received US food and drug Administration Administration ( the FDA ) granted orphan drug qualification (orphan drug Designation, ODD), for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia / lymphoma (T-cell acute lymphoblastic leukemia / lymphoma (T-ALL/LBL)) .
-
NEJM: SPK-8011 gene therapy for hemophilia A
Time of Update: 2021-12-01
After Spk-8011 treatment, the bleeding risk of patients was greatly reducedStudies believe that SPK-8011 can achieve continuous factor 8 expression in patients with hemophilia A, reducing the risk of bleeding by more than 90% .
-
2021 CSCO highlights you missed are all here~
Time of Update: 2021-11-16
2021 CSCO expert interview | Professor Zhang Yizhu: new progress in the treatment of lymphoma in children and adolescents 4.
2021 CSCO expert interview | Professor Deng Qi talks about the treatment progress of extramedullary multiple myeloma 6.
-
Nat Nanotechnol breakthrough!
Time of Update: 2021-11-16
On October 25, 2021, Ma Guanghui, Wei Wei, Martin of Peking University, and Yuhua Li of Southern Medical University from the Institute of Process Engineering of the Chinese Academy of Sciences published an online publication titled "Ferritin-based targeted delivery of arsenic to" in Nature Nanotechnology (IF=39).
-
One out of every eight people will get it. This disease has a new idea of diet therapy!
Time of Update: 2021-11-16
The research shows that regular consumption of millet can effectively prevent and reduce iron deficiency anemia .
Regular consumption of millet provides new ideas for the prevention and treatment of iron-deficiency anemia.
-
New cell immunotherapy——STAR-T for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia
Time of Update: 2021-11-16
In addition, in terms of proliferation ability, the proliferation of dual-target STAR-T cells in vivo is good, reaching a peak on the 10th day (7-14 days), and the number of copies in peripheral blood is 6.
-
Knowing Lymphology·Phase 2 Pathology Expert Talk: Combining Theory and Practice to Help Pathological Diagnosis of Lymphoma
Time of Update: 2021-11-16
Interview with Professor Xu Enwei (the video is longer, it is recommended to watch under WiFi conditions) What are the precautions for the differential diagnosis of common lymphoma and related lesions in the intestinal tract of Yimaitong?
-
Professor Song Yuqin: The new anti-CD20 monoclonal antibody otuzumab, innovative mechanism provides new treatment options for relapsed and refractory FL
Time of Update: 2021-11-16
The GADOLIN study shows that rituximab-resistant FL patients or relapsed after treatment, the use of otuzumab is still effective , And there is a survival benefit (compared with bendamustine single agent), which may be derived from the innovative mechanism of action of otuzumab .
-
New treatment strategies for elderly patients with acute myeloid leukemia
Time of Update: 2021-11-16
The low-intensity dinucleoside analog combination regimen of Cladribine + low-dose cytarabine (LDAC) alternating AZA showed high CR rates and long-lasting OS in newly diagnosed patients with a median age of 69 years .
-
Molecular Cancer Guangzhou Medical University Jiang Hua/Xu Ling found a new prognostic marker for acute myeloid leukemia in children
Time of Update: 2021-11-16
40) entitled "CircRNF220, not its linear cognate gene RNF220, regulates cell growth and is associated with relapse in pediatric acute myeloid Leukemia" research paper, which used circRNA microarray to study the expression pattern of circRNA in children with AML .
-
[Nature Sub-Journal] A new method for treating leukemia!
Time of Update: 2021-11-16
Researchers at Bar-Ilan University in Israel have revealed a new treatment method against blood cancers developed by Professor Mira Barda-Saad of Mina and Everard Goodman School of Life Sciences and his research team, which involves attacking the cytoskeleton The protein WASp, which has a unique structure in active blood cancer cells .
-
Correlation between intensity of treatment plan and prognosis in elderly patients with Hodgkin's lymphoma
Time of Update: 2021-11-16
A retrospective cohort study used the SEER-Medicare database to explore the relationship between the intensity of treatment options and the cause-specific mortality of elderly HL patients .
-
Knowing Lymphology·Phase 3 Pathology Expert Talk: How to clarify the idea of differential diagnosis of lymphoma?
Time of Update: 2021-11-16
In order to further enhance the pathologist’s ability in the clinical differential diagnosis of common tissue diseases and lymphoma, and reduce the occurrence of missed lymphoma diagnosis, the "Knowl
-
STAMP inhibitor Asciminib is expected to bring good news to CML patients!
Time of Update: 2021-11-16
Yimaitong invited Professor Wang Jianxiang from the Hematology Hospital of the Chinese Academy of Medical Sciences to combine the results of the ASCEMBL Phase III clinical study on Asciminib in chronic myeloid leukemia (CML-CP) adult patients who have previously received two or more TKI treatments Application for wonderful interpretation and review!
-
CCSC: Strong curative effect, control toxicity, and practically solve new problems in CAR-T treatment
Time of Update: 2021-11-16
This conference is fortunate to invite Professor Liang Aibin from Tongji Hospital Affiliated to Tongji University, Professor Robin Sanderson from King's College Hospital, Professor Li Ping from Tongji Hospital Affiliated to Tongji University, Doctor Ye Shiguang from Tongji Hospital Affiliated to Tongji University, and many top domestic experts as speakers and discussions Guests, focusing on cutting-edge topics in the field of CAR-T cell therapy, conducted in-depth discussions and exchanges on Fosun Kate’s CAR-T cell therapy drug Yikaida® (Akilunza injection) .
-
Professor Liang Aibin: New targeted drug selinexor brings new hope to DLBCL patients
Time of Update: 2021-11-16
Professor Liang Aibin, Doctoral Supervisor, Professor, Deputy Dean of Tongji Hospital, Director of Hematology Oncology Center, Deputy Secretary-General of the Experimental Hematology Committee of the
